多吉美对肝癌的疗效与Ki-67及CD34表达的关系  

Therapeutic efficacy of Nexavar on liver cancer and its relation to the expression of Ki-67 and CD34

作　　者：阚和平[1] 王宇[1] 谭永法[1] 周杰[1] 

机构地区：[1]南方医科大学南方医院肝胆外科,广东广州510515

出　　处：《南方医科大学学报》2010年第8期1930-1931,1934,共3页Journal of Southern Medical University

摘　　要：目的研究多吉美对肝癌的疗效与Ki-67及CD34表达的关系。方法应用多吉美治疗肝癌28例,观察其疗效。用免疫组化法检测28例肝癌组织中Ki-67及CD34表达,计算出肿瘤微血管密度(MVD)。结果 28例患者CR0例,PR12例,SD7例,PD9例。吉美对肝癌的疗效与Ki-67阳性之间有显著正相关性。12例CR患者中,MVD计数均数为346.03±146.98。SD7例,MVD计数均数为206.03±101.34。PD9例,MVD计数均数为89.14±45.66。CR与PD患者之间,MVD计数均值有非常显著的差异。结论 Ki-67阳性染色及MVD计数高的肝癌患者使用多吉美效果好。Objective To study the therapeutic effects of Nexavar on liver cancer and its relation to the expressions of Ki-67 and CD34. Methods Twenty-eight patients with liver cancer were treated with Nexavar. The therapeutic efficacy of Nexavar on liver cancer was observed. Liver cancer tissues were examined for the expressions of Ki-67 and CD34 by immunohistochemistry. Microvessel density （MVD） was calculated according to the expression of CD34. Results Of 28 patients, none achieved a complete response （CR）, 12 had a partial response （PR）, 7 had stable disease （SD）, and 9 progressive disease （PD）. The efficacy of Nexavar was associated significantly with Ki-67 expression. The mean MVD count was 346.03± 146.98 in PR patients, and 89.14±45.66 in PD patients. There was a significant difference in MVD between PR and PD patients. Conclusion There is a better efficacy of Nexavar in treatment of liver cancer in the patients who had Ki-67-positive expression and high MVD count.

关 键 词：多吉美 肝肿瘤 KI-67蛋白 CD34细胞 微血管密度 

分 类 号：R735.7[医药卫生—肿瘤]